Probiotics and Probiotic-like Agents against Chemotherapy-Induced Intestinal Mucositis: A Narrative Review

Abstract

Cancer chemotherapy has allowed many patients to survive, but not without risks derived from its adverse effects. Drugs, such as 5-fluorouracil, irinotecan, oxaliplatin, methotrexate, and others, as well as different drug combinations trigger intestinal mucositis that may cause or contribute to anorexia, pain, diarrhea, weight loss, systemic infections, and even death. Dysbiosis is a hallmark of chemotherapy-induced intestinal mucositis and diarrhea, and, therefore, strategies aimed at modulating intestinal microbiota may be useful to counteract and prevent those dreadful effects. This narrative review offers an overview of the studies performed to test the efficacy of probiotics and probiotic-like agents against chemotherapy-induced intestinal mucositis and its consequences. Microbiota modulation through the oral administration of different probiotics (mainly strains of Lactobacillus and Bifidobacterium), probiotic mixtures, synbiotics, postbiotics, and paraprobiotics has been tested in different animal models and in some clinical trials. Regulation of dysbiosis, modulation of epithelial barrier permeability, anti-inflammatory effects, modulation of host immune response, reduction of oxidative stress, or prevention of apoptosis are the main mechanisms involved in their beneficial effects. However, the findings are limited by the great heterogeneity of the preclinical studies and the relative lack of studies in immunocompromised animals, as well as the scarce availability of results from clinical trials. Despite this, the results accumulated so far are promising. Hopefully, with the aid of these agents, intestinal mucositis will be less impactful to the cancer patient in the near future.

From the Gut to the Brain: The Role of Enteric Glial Cells and Their Involvement in the Pathogenesis of Parkinson’s Disease

“…Another possible target to consider could be the modulation of the endocannabinoid system, since cannabinoids and cannabinoid-like compounds can regulate EGC activity, directly through peroxisome proliferator-activated receptors (PPAR)α receptors by palmitoylethanolamide and indirectly through activation of PPARγ or cannabinoid type 2 receptors (under GI inflammatory conditions) [97]. Moreover, the fact that dysbiosis is present in PD patients points to the possibility of treatment with probiotics, prebiotics, or combinations (synbiotics), and others such as postbiotics or paraprobiotics [98].…”

Advancements in understanding the role of intestinal dysbacteriosis mediated mucosal immunity in IgA nephropathy

“…Analyses of fecal specimens from individuals with IgAN versus healthy controls have shown a notable reduction in microbial diversity in IgAN patients, particularly in genera such as Clostridium, Enterococcus, Lactobacillus, and Bifidobacterium, whereas a higher proportion of genera like Ruminococcaceae, Fusobacteriaceae, Prevotellaceae, and Streptococcaceae were observed. The reduction in some probiotics, such as Lactobacillus and Bifidobacterium, may be closely related to the use of antibiotics [97] or immunosuppressants [98], as well as low-protein diets [99,100]. Therefore, it is crucial to control for these confounding factors in research.…”

Advancements in the impact of human microbiota and probiotics on leukemia

“…Furthermore, probiotics can also counteract the loss of mucin-secreting goblet cells, or regulate the expression of genes that encode mucin-secreting, ensuring the proper functioning of these cells. In addition, probiotic treatment can improve the intestinal immune barrier by enhancing the production of intestinal IgA ( López-Gómez et al, 2023 ).…”